Semaglutide vs Retatrutide: What's the Difference?
Semaglutide and retatrutide are two of the most talked-about metabolic peptides. Both are used for weight management, but they work differently. Here's a clear comparison.
Semaglutide: the GLP-1 agonist
Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone to slow gastric emptying, reduce appetite, and improve blood sugar control. It's the compound behind well-known branded medications and has an extensive track record.
Retatrutide: the triple agonist
Retatrutide is newer and more ambitious — it's a triple agonist targeting three receptors at once: GLP-1, GIP, and glucagon. Hitting glucagon in addition to GLP-1 and GIP is thought to drive additional fat metabolism and energy expenditure, and early trial data has shown notably strong weight-loss results.
Key differences
- Mechanism: semaglutide hits one receptor (GLP-1); retatrutide hits three (GLP-1 + GIP + glucagon).
- Maturity: semaglutide is well-established; retatrutide is newer with a shorter track record.
- Titration: both are titrated up slowly to manage side effects like nausea.
What they share
Both are typically dosed once weekly, both require slow titration, and both work best paired with the fundamentals — protein intake, resistance training, and consistency. Whichever you track, logging your weekly dose and weight is what tells you whether it's working.
BioHack's peptide library has complete profiles for both — molecular data, titration schedules, and mechanisms.
Frequently asked questions
What's the difference between semaglutide and retatrutide?
Semaglutide is a single GLP-1 receptor agonist and is FDA-approved (Ozempic/Wegovy). Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, and is still investigational — not FDA-approved.
Is retatrutide better than semaglutide?
Trial data for retatrutide has shown notable results, but cross-trial comparisons aren't clean, and retatrutide lacks the long-term safety data that comes with approval. Semaglutide has a much longer track record.
Is retatrutide approved?
No. Retatrutide remains investigational and is in clinical trials. Semaglutide is FDA-approved.
BioHack turns everything above into a tool — a reconstitution calculator, dose advisor, cycle planner, and 45-peptide library, all in one app.
Open BioHack →For educational and research purposes only. Not medical advice. Consult a physician before starting any peptide protocol. BioHack is a tracking tool and does not sell peptides.